4.4 Article

Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue

Journal

MOLECULAR BRAIN
Volume 5, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1756-6606-5-35

Keywords

Induced pluripotent stem cells; Parkinson's disease; Parkin; Oxidative stress; Mitochondria; alpha-synuclein

Categories

Funding

  1. Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)
  2. Japan Science and Technology Agency (JST)
  3. Japan Society for the Promotion of Science (JSPS)
  4. Keio Kanrinmaru Project
  5. MEXT
  6. Grants-in-Aid for Scientific Research [23790238, 24651265, 23659102, 23618010, 23129506, 23689017, 23390041, 23650194] Funding Source: KAKEN

Ask authors/readers for more resources

Background: Parkinson's disease (PD) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the pathophysiology of human PARK2. Results: Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an accumulation of alpha-synuclein, alpha-synuclein accumulation was observed in the postmortem brain of one of the donor patients. This accumulation was also seen in the iPSC-derived neurons in the same patient. Conclusions: Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology. These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug screening and potential modified therapies for PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available